GSK (NYSE:GSK) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) Head to Head Review

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and GSK (NYSE:GSK) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.

Profitability

This table compares Eyepoint Pharmaceuticals and GSK’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
GSK	14.56%	43.23%	11.60%

Volatility & Risk

Eyepoint Pharmaceuticals has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Eyepoint Pharmaceuticals and GSK, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1	6	4	0	2.27
GSK	2	7	1	1	2.09

Eyepoint Pharmaceuticals currently has a consensus price target of $25.70, suggesting a potential upside of 642.77%. GSK has a consensus price target of $56.50, suggesting a potential upside of 21.46%. Given Eyepoint Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Eyepoint Pharmaceuticals is more favorable than GSK.

Institutional & Insider Ownership

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Eyepoint Pharmaceuticals and GSK”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37 million	9.51	-$231.96 million	($3.74)	-0.93
GSK	$33.20 billion	2.83	$7.54 billion	$3.20	14.54

GSK has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Summary

GSK beats Eyepoint Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.